Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05129969

Registry Platform Ovarian and Endometrial Cancer

SMARAGD - Clinical Research Platform on Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancer Treatment and Outcomes

Status
Recruiting
Phase
Study type
Observational
Enrollment
1,975 (estimated)
Sponsor
iOMEDICO AG · Industry
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with advanced or metastatic ovarian cancer (OC) or advanced or metastatic endometrial cancer (EC) in Germany.

Detailed description

SMARAGD is a national, prospective, open-label, longitudinal, non-interventional multicenter cohort study (tumour registry platform) to describe treatment in routine clinical practice of ovarian, fallopian tube, primary peritoneal and endometrial patients in routine care in Germany. The registry will follow patients for up to three years with the aim to identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. Health-related quality of life (HRQoL) will be evaluated for up to three years.

Conditions

Interventions

TypeNameDescription
OTHERPhysician's choice according to patient's needs.Routine care as per site standard.

Timeline

Start date
2021-11-25
Primary completion
2030-12-01
Completion
2030-12-01
First posted
2021-11-22
Last updated
2026-01-28

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT05129969. Inclusion in this directory is not an endorsement.

Registry Platform Ovarian and Endometrial Cancer (NCT05129969) · Clinical Trials Directory